2015 Q2 Form 10-Q Financial Statement
#000114420415030158 Filed on May 13, 2015
Income Statement
| Concept | 2015 Q2 | 2015 Q1 | 2014 Q4 |
|---|---|---|---|
| Revenue | $2.190M | $5.860M | $8.972M |
| YoY Change | 21.87% | -5.04% | -6.56% |
| Cost Of Revenue | $1.180M | $2.198M | $3.080M |
| YoY Change | 17.41% | 0.32% | 1.99% |
| Gross Profit | $1.010M | $3.662M | $5.896M |
| YoY Change | 27.53% | -7.99% | -10.49% |
| Gross Profit Margin | 46.12% | 62.49% | 65.72% |
| Selling, General & Admin | $2.300M | $4.833M | $6.160M |
| YoY Change | -37.09% | 7.3% | 7.32% |
| % of Gross Profit | 227.72% | 131.98% | 104.48% |
| Research & Development | $270.0K | $208.0K | $420.0K |
| YoY Change | -1.1% | -25.18% | 75.0% |
| % of Gross Profit | 26.73% | 5.68% | 7.12% |
| Depreciation & Amortization | $90.00K | $83.00K | $80.00K |
| YoY Change | 28.57% | 29.69% | 33.33% |
| % of Gross Profit | 8.91% | 2.27% | 1.36% |
| Operating Expenses | $2.580M | $5.041M | $6.570M |
| YoY Change | -34.33% | 5.42% | 10.05% |
| Operating Profit | -$1.570M | -$1.379M | -$674.0K |
| YoY Change | -49.95% | 71.95% | -209.24% |
| Interest Expense | $0.00 | $1.000K | $0.00 |
| YoY Change | -100.0% | -50.0% | -100.0% |
| % of Operating Profit | |||
| Other Income/Expense, Net | |||
| YoY Change | |||
| Pretax Income | -$1.570M | -$1.380M | -$680.0K |
| YoY Change | -49.97% | 71.64% | -213.33% |
| Income Tax | $0.00 | $0.00 | $0.00 |
| % Of Pretax Income | |||
| Net Earnings | -$1.570M | -$1.380M | -$676.0K |
| YoY Change | -49.97% | 71.64% | -213.23% |
| Net Earnings / Revenue | -71.69% | -23.55% | -7.53% |
| Basic Earnings Per Share | -$0.09 | ||
| Diluted Earnings Per Share | -$98.00K | -$0.09 | -$44.04K |
| COMMON SHARES | |||
| Basic Shares Outstanding | 15.89M shares | 15.89M shares | 15.46M shares |
| Diluted Shares Outstanding | 15.89M shares |
Balance Sheet
| Concept | 2015 Q2 | 2015 Q1 | 2014 Q4 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $3.760M | $5.020M | $2.930M |
| YoY Change | -48.84% | -9.06% | 78.66% |
| Cash & Equivalents | $3.760M | $5.021M | $2.926M |
| Short-Term Investments | |||
| Other Short-Term Assets | $470.0K | $670.0K | $1.400M |
| YoY Change | -35.62% | 13.56% | -22.22% |
| Inventory | $3.710M | $3.277M | $3.292M |
| Prepaid Expenses | |||
| Receivables | $1.250M | $3.468M | $5.836M |
| Other Receivables | $0.00 | $0.00 | $0.00 |
| Total Short-Term Assets | $9.180M | $12.44M | $13.46M |
| YoY Change | -32.87% | 11.33% | 19.32% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $2.860M | $2.558M | $2.599M |
| YoY Change | 13.99% | 1.51% | 1.37% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | |||
| YoY Change | |||
| Total Long-Term Assets | $2.860M | $2.558M | $2.599M |
| YoY Change | -53.01% | -58.07% | -57.68% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $9.180M | $12.44M | $13.46M |
| Total Long-Term Assets | $2.860M | $2.558M | $2.599M |
| Total Assets | $12.04M | $14.99M | $16.06M |
| YoY Change | -39.07% | -13.18% | -7.82% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $650.0K | $1.231M | $667.0K |
| YoY Change | -53.54% | 24.34% | -34.03% |
| Accrued Expenses | $2.300M | $3.230M | $3.690M |
| YoY Change | -25.32% | 12.15% | 29.47% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $3.580M | $5.524M | $5.241M |
| YoY Change | -39.85% | 29.55% | 13.34% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | $100.0K | $100.0K | $100.0K |
| YoY Change | -50.0% | -50.0% | -50.0% |
| Total Long-Term Liabilities | $100.0K | $100.0K | $100.0K |
| YoY Change | -50.0% | -50.0% | -50.0% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $3.580M | $5.524M | $5.241M |
| Total Long-Term Liabilities | $100.0K | $100.0K | $100.0K |
| Total Liabilities | $3.680M | $5.620M | $5.341M |
| YoY Change | -40.16% | 26.01% | 10.72% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$14.60M | -$13.22M | |
| YoY Change | 135.89% | 145.48% | |
| Common Stock | $54.71M | $54.68M | |
| YoY Change | 22.59% | 25.35% | |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | $30.74M | $30.74M | |
| YoY Change | 19.91% | 19.91% | |
| Treasury Stock Shares | 9.233M shares | 9.233M shares | |
| Shareholders Equity | $8.360M | $9.370M | $10.72M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $12.04M | $14.99M | $16.06M |
| YoY Change | -39.07% | -13.16% | -7.82% |
Cashflow Statement
| Concept | 2015 Q2 | 2015 Q1 | 2014 Q4 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$1.570M | -$1.380M | -$676.0K |
| YoY Change | -49.97% | 71.64% | -213.23% |
| Depreciation, Depletion And Amortization | $90.00K | $83.00K | $80.00K |
| YoY Change | 28.57% | 29.69% | 33.33% |
| Cash From Operating Activities | -$1.400M | $2.130M | -$1.740M |
| YoY Change | -29.65% | -27.8% | -302.33% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | -$390.0K | $42.00K | -$190.0K |
| YoY Change | 550.0% | 147.06% | 58.33% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $0.00 | $10.00K | $0.00 |
| YoY Change | |||
| Cash From Investing Activities | -$380.0K | -$40.00K | -$190.0K |
| YoY Change | 533.33% | 100.0% | 58.33% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | $0.00 | ||
| YoY Change | -100.0% | ||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 520.0K | 0.000 | -100.0K |
| YoY Change | -86.6% | -100.0% | -166.67% |
| NET CHANGE | |||
| Cash From Operating Activities | -1.400M | 2.130M | -1.740M |
| Cash From Investing Activities | -380.0K | -40.00K | -190.0K |
| Cash From Financing Activities | 520.0K | 0.000 | -100.0K |
| Net Change In Cash | -1.260M | 2.090M | -2.030M |
| YoY Change | -168.85% | -46.13% | -328.09% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$1.400M | $2.130M | -$1.740M |
| Capital Expenditures | -$390.0K | $42.00K | -$190.0K |
| Free Cash Flow | -$1.010M | $2.088M | -$1.550M |
| YoY Change | -47.67% | -28.81% | -258.16% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2015Q1 | dei |
Entity Registrant Name
EntityRegistrantName
|
ProPhase Labs, Inc. | |
| CY2015Q1 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0000868278 | |
| CY2015Q1 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
| CY2015Q1 | dei |
Entity Filer Category
EntityFilerCategory
|
Smaller Reporting Company | |
| CY2015Q1 | dei |
Trading Symbol
TradingSymbol
|
PRPH | |
| CY2015Q2 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
15892296 | shares |
| CY2015Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: bold italic 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Use of Estimates</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The preparation of financial statements and the accompanying notes thereto, in conformity with GAAP, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the respective reporting periods. Examples include the provision for bad debt, sales returns and allowances, inventory obsolescence, useful lives of property and equipment and intangible assets, impairment of property and equipment and intangible assets, income tax valuations and assumptions related to accrued advertising. When providing for the appropriate sales returns, allowances, cash discounts and cooperative incentive promotion costs (“Sales Allowances”), we apply a uniform and consistent method for making certain assumptions for estimating these provisions. These estimates and assumptions are based on historical experience, current trends and other factors that management believes to be relevant at the time the financial statements are prepared. Management reviews the accounting policies, assumptions, estimates and judgments on a quarterly basis. Actual results could differ from those estimates.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Our primary product, Cold-EEZE<font style="FONT-FAMILY:Symbol"><sup style="font-style:normal">Ò</sup></font> <sup style="font-style:normal"></sup>Cold Remedy lozenges, utilizes a proprietary zinc gluconate formulation which has been clinically proven to reduce the severity and duration of common cold symptoms. Factors considered in estimating the appropriate sales returns and allowances for this product include it being (i) a unique product with limited competitors, (ii) competitively priced, (iii) promoted, (iv) unaffected for remaining shelf-life as there is no product expiration date and (v) monitored for inventory levels at major customers and third-party consumption data. In addition to Cold-EEZE<sup style="font-style:normal">®</sup> Cold Remedy lozenges, we market and distribute a variety of Cold-EEZE<sup style="font-style:normal">®</sup> Cold Remedy QuickMelts<sup style="font-style:normal">®</sup> and a Cold-EEZE<sup style="font-style:normal">®</sup> Cold Remedy Oral Spray. We also manufacture, market and distribute an organic cough drop and a Vitamin C supplement (“Organix<sup style="font-style:normal">®</sup>”). Each of the Cold-EEZE<sup style="font-style:normal">®</sup> Cold Remedy Oral Spray and QuickMelts<sup style="font-style:normal">®</sup> products, and Organix<sup style="font-style:normal">®</sup> products carry shelf-life expiration dates for which we aggregate such new product market experience data and update our sales returns and allowances estimates accordingly. Sales allowances estimates are tracked at the specific customer and product line levels and are tested on an annual historical basis, and reviewed quarterly. Additionally, we monitor current developments by customer, market conditions and any other occurrences that could affect the expected provisions relative to net sales for the period presented.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2015Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
9370000 | USD |
| CY2014Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
10716000 | USD |
| CY2015Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
14994000 | USD |
| CY2015Q1 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i>Concentration of Risks</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Future revenues, costs, margins, and profits will continue to be influenced by our ability to maintain our manufacturing availability and capacity together with our marketing and distribution capabilities and the regulatory requirements associated with the development of OTC and other personal care products in order to compete on a national level and/or international level.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Our business is subject to federal and state laws and regulations adopted for the health and safety of users of our products. Our OTC cold remedy <sup style="font-style:normal"> </sup>products are subject to regulations by various federal, state and local agencies, including the Food and Drug Administration (“FDA”) and, as applicable, the Homeopathic Pharmacopoeia of the United States.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Financial instruments that potentially subject us to significant concentrations of credit risk consist principally of cash investments and trade accounts receivable.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">We maintain cash and cash equivalents with certain major financial institutions. As of March 31, 2015, our cash balance was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.0</font> million and our bank balance was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.3</font> million. Of the total bank balance, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">582,000</font> was covered by federal depository insurance and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.7</font> million was uninsured at March 31, 2015.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong> </strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Trade accounts receivable potentially subject us to credit concentrations from time-to-time as a consequence of the timing, payment pattern and ultimate purchase volumes or shipping schedules with our customers. We extend credit to our customers based upon an evaluation of the customer’s financial condition and credit history and generally we do not require collateral. Our broad range of customers includes many large national chain, regional, specialty and local retail stores. These credit concentrations may impact our overall exposure to credit risk, either positively or negatively, in that our customers may be similarly affected by changes in economic, regulatory or other conditions that may impact the timing and collectability of amounts due to us. As a consequence of an evaluation of our customer’s financial condition, payment patterns, balance due us and other factors, we did not offset our account receivable with an allowance for bad debt at March 31, 2015 and December 31, 2014.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong> </strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Our revenues are principally generated from the sale of OTC cold remedy products which represented approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 93</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 95</font>% of total revenues for each of the three months ended March 31, 2015 and 2014, respectively. A significant portion of our business is highly seasonal, which causes major variations in operating results from quarter to quarter. The third and fourth quarters generally represent the largest sales volume for the OTC cold remedy products. For the three months ended March 31, 2015 and 2014, our net sales were principally related to domestic markets.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2015Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
5021000 | USD |
| CY2014Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
2926000 | USD |
| CY2015Q1 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
3468000 | USD |
| CY2014Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
5836000 | USD |
| CY2015Q1 | us-gaap |
Inventory Net
InventoryNet
|
3277000 | USD |
| CY2014Q4 | us-gaap |
Inventory Net
InventoryNet
|
3292000 | USD |
| CY2015Q1 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
670000 | USD |
| CY2014Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
1404000 | USD |
| CY2015Q1 | us-gaap |
Assets Current
AssetsCurrent
|
12436000 | USD |
| CY2014Q4 | us-gaap |
Assets Current
AssetsCurrent
|
13458000 | USD |
| CY2015Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
2558000 | USD |
| CY2014Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
2599000 | USD |
| CY2015Q1 | us-gaap |
Assets
Assets
|
14994000 | USD |
| CY2014Q4 | us-gaap |
Assets
Assets
|
16057000 | USD |
| CY2015Q1 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1231000 | USD |
| CY2014Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
667000 | USD |
| CY2015Q1 | us-gaap |
Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
|
3232000 | USD |
| CY2014Q4 | us-gaap |
Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
|
3685000 | USD |
| CY2015Q1 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
1061000 | USD |
| CY2014Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
889000 | USD |
| CY2015Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
5524000 | USD |
| CY2014Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
5241000 | USD |
| CY2015Q1 | us-gaap |
Liabilities Other Than Longterm Debt Noncurrent
LiabilitiesOtherThanLongtermDebtNoncurrent
|
100000 | USD |
| CY2014Q4 | us-gaap |
Liabilities Other Than Longterm Debt Noncurrent
LiabilitiesOtherThanLongtermDebtNoncurrent
|
100000 | USD |
| CY2015Q1 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2014Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2015Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
13000 | USD |
| CY2014Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
13000 | USD |
| CY2015Q1 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
54698000 | USD |
| CY2014Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
54664000 | USD |
| CY2015Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-14599000 | USD |
| CY2014Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-13219000 | USD |
| CY2015Q1 | us-gaap |
Treasury Stock Value
TreasuryStockValue
|
30742000 | USD |
| CY2014Q4 | us-gaap |
Treasury Stock Value
TreasuryStockValue
|
30742000 | USD |
| CY2014Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
16057000 | USD |
| CY2015Q1 | us-gaap |
Inventory Adjustments
InventoryAdjustments
|
505000 | USD |
| CY2014Q4 | us-gaap |
Inventory Adjustments
InventoryAdjustments
|
797000 | USD |
| CY2015Q1 | us-gaap |
Cash Fdic Insured Amount
CashFDICInsuredAmount
|
582000 | USD |
| CY2015Q1 | us-gaap |
Cash Uninsured Amount
CashUninsuredAmount
|
4700000 | USD |
| CY2015Q1 | us-gaap |
Due From Banks
DueFromBanks
|
5300000 | USD |
| CY2014 | us-gaap |
Sales Allowances Goods
SalesAllowancesGoods
|
129000 | USD |
| CY2015Q1 | us-gaap |
Sales Allowances Goods
SalesAllowancesGoods
|
55000 | USD |
| CY2014Q1 | us-gaap |
Marketing And Advertising Expense
MarketingAndAdvertisingExpense
|
3400000 | USD |
| CY2015Q1 | us-gaap |
Marketing And Advertising Expense
MarketingAndAdvertisingExpense
|
3100000 | USD |
| CY2015Q1 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
4424000 | USD |
| CY2014Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
4341000 | USD |
| CY2015Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0005 | |
| CY2014Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0005 | |
| CY2015Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
50000000 | shares |
| CY2014Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
50000000 | shares |
| CY2015Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
25125113 | shares |
| CY2014Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
25125113 | shares |
| CY2015Q1 | us-gaap |
Treasury Stock Shares
TreasuryStockShares
|
9232817 | shares |
| CY2014Q4 | us-gaap |
Treasury Stock Shares
TreasuryStockShares
|
9232817 | shares |
| CY2015Q1 | us-gaap |
Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
|
869000 | USD |
| CY2015Q1 | us-gaap |
Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
|
1125000 | USD |
| CY2015Q1 | us-gaap |
Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
|
1025000 | USD |
| CY2015Q1 | us-gaap |
Contractual Obligation Due In Fourth Year
ContractualObligationDueInFourthYear
|
0 | USD |
| CY2015Q1 | us-gaap |
Contractual Obligation Due In Fifth Year
ContractualObligationDueInFifthYear
|
0 | USD |
| CY2015Q1 | us-gaap |
Contractual Obligation Due After Fifth Year
ContractualObligationDueAfterFifthYear
|
3019000 | USD |
| CY2012 | us-gaap |
Payments For Legal Settlements
PaymentsForLegalSettlements
|
2100000 | USD |
| CY2014 | prph |
Settlement Benefit
SettlementBenefit
|
10000 | USD |
| CY2014Q4 | prph |
Additional Royalties And Commissions Accrual Interest Percentage
AdditionalRoyaltiesAndCommissionsAccrualInterestPercentage
|
0.0325 | pure |
| CY2014 | prph |
Additional Royalties And Commissions Payable Installment Amount
AdditionalRoyaltiesAndCommissionsPayableInstallmentAmount
|
100000 | USD |
| CY2012Q4 | prph |
Additional Royalties And Commissions Payable Installment Amount
AdditionalRoyaltiesAndCommissionsPayableInstallmentAmount
|
100000 | USD |
| CY2015Q1 | prph |
Additional Annual Installment Includes In Other Current Liability
AdditionalAnnualInstallmentIncludesInOtherCurrentLiability
|
100000 | USD |
| CY2014Q4 | prph |
Additional Annual Installment Includes In Other Long Term Obligation
AdditionalAnnualInstallmentIncludesInOtherLongTermObligation
|
100000 | USD |
| CY2015Q1 | prph |
Equity Method Investment Ownership Percentage Required For Rights Exercisable Under Right Agreement
EquityMethodInvestmentOwnershipPercentageRequiredForRightsExercisableUnderRightAgreement
|
0.15 | pure |
| CY2014Q1 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
6171000 | USD |
| CY2015Q1 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
5860000 | USD |
| CY2014Q1 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
2191000 | USD |
| CY2015Q1 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
2198000 | USD |
| CY2014Q1 | us-gaap |
Gross Profit
GrossProfit
|
3980000 | USD |
| CY2015Q1 | us-gaap |
Gross Profit
GrossProfit
|
3662000 | USD |
| CY2014Q1 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
2997000 | USD |
| CY2015Q1 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
2812000 | USD |
| CY2014Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1507000 | USD |
| CY2015Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2021000 | USD |
| CY2014Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
278000 | USD |
| CY2015Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
208000 | USD |
| CY2014Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
4782000 | USD |
| CY2015Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
5041000 | USD |
| CY2014Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-802000 | USD |
| CY2015Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-1379000 | USD |
| CY2014Q1 | us-gaap |
Interest Expense
InterestExpense
|
2000 | USD |
| CY2015Q1 | us-gaap |
Interest Expense
InterestExpense
|
1000 | USD |
| CY2014Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-804000 | USD |
| CY2015Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-1380000 | USD |
| CY2014Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | USD |
| CY2015Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | USD |
| CY2014Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-804000 | USD |
| CY2015Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-1380000 | USD |
| CY2014Q1 | us-gaap |
Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
|
-0.05 | |
| CY2015Q1 | us-gaap |
Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
|
-0.09 | |
| CY2014Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-804000 | USD |
| CY2015Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-1380000 | USD |
| CY2014Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
16469000 | shares |
| CY2015Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
15892000 | shares |
| CY2014Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.05 | |
| CY2015Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.09 | |
| CY2014Q1 | prph |
Dilutive Securities Options Earnings Per Share Value
DilutiveSecuritiesOptionsEarningsPerShareValue
|
0 | USD |
| CY2015Q1 | prph |
Dilutive Securities Options Earnings Per Share Value
DilutiveSecuritiesOptionsEarningsPerShareValue
|
0 | USD |
| CY2015Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-1380000 | USD |
| CY2014Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.05 | |
| CY2015Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.09 | |
| CY2015Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
15892000 | shares |
| CY2015Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
34000 | USD |
| CY2014Q1 | us-gaap |
Depreciation
Depreciation
|
64000 | USD |
| CY2015Q1 | us-gaap |
Depreciation
Depreciation
|
83000 | USD |
| CY2014Q1 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
0 | USD |
| CY2015Q1 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
5000 | USD |
| CY2014Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
64000 | USD |
| CY2015Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
34000 | USD |
| CY2014Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-2463000 | USD |
| CY2015Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-2368000 | USD |
| CY2014Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-309000 | USD |
| CY2015Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-15000 | USD |
| CY2014Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-19000 | USD |
| CY2015Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
564000 | USD |
| CY2014Q1 | prph |
Increase Decrease In Accrued Marketing Costs
IncreaseDecreaseInAccruedMarketingCosts
|
35000 | USD |
| CY2015Q1 | prph |
Increase Decrease In Accrued Marketing Costs
IncreaseDecreaseInAccruedMarketingCosts
|
-453000 | USD |
| CY2014Q1 | us-gaap |
Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
|
-839000 | USD |
| CY2015Q1 | us-gaap |
Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
|
-906000 | USD |
| CY2014Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
2951000 | USD |
| CY2015Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
2132000 | USD |
| CY2014Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
17000 | USD |
| CY2015Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
42000 | USD |
| CY2014Q1 | us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
0 | USD |
| CY2015Q1 | us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
5000 | USD |
| CY2014Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-17000 | USD |
| CY2015Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-37000 | USD |
| CY2014Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
947000 | USD |
| CY2015Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
0 | USD |
| CY2014Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
947000 | USD |
| CY2015Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
0 | USD |
| CY2014Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
3881000 | USD |
| CY2015Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
2095000 | USD |
| CY2013Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
1638000 | USD |
| CY2014Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
5519000 | USD |
| CY2014Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
64000 | USD |
| CY2015Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
34000 | USD |
| CY2014 | us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
3600000 | USD |
| CY2015Q1 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
816000 | USD |
| CY2014Q4 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
798000 | USD |
| CY2015Q1 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
207000 | USD |
| CY2014Q4 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
418000 | USD |
| CY2015Q1 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
2254000 | USD |
| CY2014Q4 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
2076000 | USD |
| CY2015Q1 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
45 | |
| CY2015Q1 | prph |
Cash Less Exercise Of Right Terms
CashLessExerciseOfRightTerms
|
In the event of a cashless exercise of the Right and the acquirer has acquired less than 50% beneficial ownership of the Company | |
| CY2015Q1 | prph |
Share Based Compensation Arrangement By Share Based Payment Option Expiration Terms
ShareBasedCompensationArrangementByShareBasedPaymentOptionExpirationTerms
|
No incentive stock option could be exercisable more than ten years after the date of grant or five years after the date of grant where the individual owns more than ten percent of the total combined voting power of all classes of stock. Stockholders approved the 1997 Plan in Fiscal 1998 | |
| CY2014Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
16469000 | shares |
| CY2015Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
15892000 | shares |
| CY2015Q1 | prph |
Percentage Of Discount On Exercise Of Right
PercentageOfDiscountOnExerciseOfRight
|
0.5 | pure |
| CY2014Q1 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
1637500 | shares |
| CY2015Q1 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
1739500 | shares |
